Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $68.20 is 2.37% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 69.33||$ 110.20|
|Low:||$ 68.13||$ 66.62|
ETFs with CELG as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|6.59%||iShares Nasdaq Biotechnology Index Fund (IBB)||-14.30 (-12.10%)|
|4.09%||ARK Genomic Revolution Multi-Sector ETF (ARKG)||-3.03 (-9.79%)|
|0.82%||Madrona Domestic ETF (FWDD)||-5.43 (-10.16%)|
|0%||Proshares UltraPro Nasdaq Biotechnology (UBIO)||-15.69 (-38.17%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Celgene Corporation, together with its subsidiaries (collectively "we," "our," "us," "Celgene" or the "Company"), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Celgene Corporation was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID®, POMALYST®/IMNOVID®, OTEZLA®, ABRAXANE®, VIDAZA®, azacitidine for injection (generic version of VIDAZA®), THALOMID® (sold as THALOMID® or Thalidomide Celgene® outside of the U.S.) and IDHIFA®. IDHIFA® was approved by the U.S. ... More ...
Nasdaq Official Price
Dec. 14, 2018
Dec. 14, 2018